Molecular staging of colorectal cancer in African-American and caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27kip-1

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 403-409

  Grizzle, William E ^a   Manne, Upender ^a   Weiss, Heide L ^b   Jhala, Nirag ^a   Talley, Lynya ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer; Molecular staging; Prognosis

Indexed keywords

MUCIN CORE PROTEIN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ETHNIC DIFFERENCE; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOCARCINOMA; AFRICAN AMERICANS; CA-15-3 ANTIGEN; CASE MANAGEMENT; CELL CYCLE PROTEINS; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036466880     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1617     Document Type: Short Survey

References (43)

1. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
2. Advanced colorectal cancer: Quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil
3. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer
4. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
5. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas
6. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
7. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
8. Molecular and histopathologic changes in the development of colorectal neoplasia
9. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia
10. Nuclear accumulation of p53 in colorectal adenocarcinoma: Prognostic importance differs with race and location of the tumor
11. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas
12. Clinical and pathological associations with allelic loss in colorectal carcinoma
13. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma
14. The molecular characterization of colorectal neoplasia in translational research
15. Tumour markers of prognosis in colorectal cancer
16. Bcl-2 expression in human colorectal adenomas and carcinomas
17. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas
18. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis
19. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance
20. Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence
21. The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence
22. Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer
23. The immunohistochemical expression of BCL-2 oncoprotein in colorectal adenocarcinoma
24. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma
25. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma
26. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: Correlation with tumour stage and patient survival
27. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
28. Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer
29. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2
30. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas
31. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance
32. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma
33. Colorectal mucin histochemistry in health and disease: A critical review
34. Heterogeneity of mucin gene expression in normal and neoplastic tissues
35. Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis(x) expression
36. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas
37. Muc-1 expression as a predictor of the curative endoscopic treatment of submucossaly invasive colorectal carcinoma
38. Immunoreative MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer
39. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
40. Multivariate analysis of tissue-based prognostic markers in stage II-III colorectal carcinoma
41. Kip1 protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas
42. p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer
43. Nuclear accumulation of p53 in colorectal adenocarcinoma: Prognostic importance differs with race, age and location of the tumor